Brought to you by 
Achillion gets $225mm equity investment from JJDC
27 May 2015
Executive Summary
Johnson & Johnson Development Corp. made a $225mm equity investment in Achillion Pharmaceuticals Inc., buying about 18.4mm new unregistered shares at $12.25 each (a 28% premium). Concurrently, Achillion licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to develop and commercialize hepatitis C assets including ACH3102, ACH3422, and sovaprevir.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Achillion gets $225mm equity investment from JJDC
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice